Benitec Biopharma Inc. (BNTC)
Nasdaq · Healthcare · Biotechnology
$9.23+2.78%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $322M
- 52-week range
- $8.52 – $16.76
- 52-week change
- −34.26%
- EPS (trailing)
- −$0.98
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Jun 2026
- Net income
- −$45.5M
- Diluted EPS
- −$0.98
- Free cash flow
- −$16.6M
From the company’s annual report on SEC EDGAR.
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Headquarters: Hayward, United States · 24 employees · benitec.com